214 related articles for article (PubMed ID: 19380447)
21. Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels.
Hess G; Hill J; Clough J; Hulnick S; Nordyke RJ
Curr Med Res Opin; 2008 Mar; 24(3):815-9. PubMed ID: 18257979
[TBL] [Abstract][Full Text] [Related]
22. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
Spaepen E; Demarteau N; Van Belle S; Annemans L
Oncologist; 2008 May; 13(5):596-607. PubMed ID: 18515745
[TBL] [Abstract][Full Text] [Related]
23. Phase III clinical trials with darbepoetin: implications for clinicians.
Glaspy J
Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
[TBL] [Abstract][Full Text] [Related]
24. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
25. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
Vansteenkiste J; Pirker R; Massuti B; Barata F; Font A; Fiegl M; Siena S; Gateley J; Tomita D; Colowick AB; Musil J;
J Natl Cancer Inst; 2002 Aug; 94(16):1211-20. PubMed ID: 12189224
[TBL] [Abstract][Full Text] [Related]
26. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
27. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
[TBL] [Abstract][Full Text] [Related]
28. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
[TBL] [Abstract][Full Text] [Related]
29. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
Hesketh PJ; Arena F; Patel D; Austin M; D'Avirro P; Rossi G; Colowick A; Schwartzberg L; Bertoli LF; Cole JT; Demetri G; Dessypris E; Dobbs T; Eisenberg P; Fleischman R; Hall J; Hoffman PC; Laber DA; Leonard J; Lester EP; McCachren S; McMeekin S; Meza L; Miller DS; Nand S; Oliff I; Paroly W; Pawl L; Perez A; Raftopoulos H; Rigas J; Rowland K; Scullin DC; Tezcan H; Waples J; Ward J; Yee LK
Cancer; 2004 Feb; 100(4):859-68. PubMed ID: 14770445
[TBL] [Abstract][Full Text] [Related]
30. Treatment of anemia with darbepoetin alfa in heart failure.
Abraham WT; Anand IS; Klapholz M; Ponikowski P; Scarlata D; Wasserman SM; van Veldhuisen DJ
Congest Heart Fail; 2010; 16(3):87-95. PubMed ID: 20557327
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
[TBL] [Abstract][Full Text] [Related]
32. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
Canon JL; Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Legg J; Pujol B; Bridges K
Med Oncol; 2012 Sep; 29(3):2291-9. PubMed ID: 22081263
[TBL] [Abstract][Full Text] [Related]
33. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.
Nagel S; Kellner O; Engel-Riedel W; Guetz S; Schumann C; Gieseler F; Schuette W
Clin Lung Cancer; 2011 Jan; 12(1):62-9. PubMed ID: 21273182
[TBL] [Abstract][Full Text] [Related]
34. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
Charu V; Belani CP; Gill AN; Bhatt M; Tomita D; Rossi G; Ben-Jacob A
Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062
[TBL] [Abstract][Full Text] [Related]
36. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
Couture F; Turner AR; Melosky B; Xiu L; Plante RK; Lau CY; Quirt I
Oncologist; 2005 Jan; 10(1):63-71. PubMed ID: 15632253
[TBL] [Abstract][Full Text] [Related]
37. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience.
Quirt I; Kovacs M; Couture F; Turner AR; Noble M; Burkes R; Dolan S; Plante RK; Lau CY; Chang J
Oncologist; 2006 Jan; 11(1):73-82. PubMed ID: 16401716
[TBL] [Abstract][Full Text] [Related]
38. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
Boccia R; Lillie T; Tomita D; Balducci L
Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247
[TBL] [Abstract][Full Text] [Related]
39. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.
Canon JL; Vansteenkiste J; Bodoky G; Mateos MV; Bastit L; Ferreira I; Rossi G; Amado RG
J Natl Cancer Inst; 2006 Feb; 98(4):273-84. PubMed ID: 16478746
[TBL] [Abstract][Full Text] [Related]
40. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G
J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
